Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LI Fang ¹ , YIN Lei ¹ , YANG Haidong ² ,  CHEN Lizhang ¹

1. Department of Epidemiology and Health Statistics, School of Xiangya Public Health, Central South University, Changsha, 410078, P.R.China;
2. Department of Laboratory, People’s Hospital of Wuqing District, Tianjin, 301700, P.R.China;

Corresponding?author：

CHEN Lizhang, Email: liche4005@126.com

Keywords：

Methamphetamine; Psychotic disorders; Quetiapine; Randomized controlled trial; Network meta-analysis

DOI：

10.7507/1672-2531.201702036

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo systematically review the efficacy of different drugs for patients with methamphetamine-induced psychotic disorders by network meta-analysis.MethodsAn electronical search was conducted in PubMed, The Cochrane Library, Web of Science, EMbase, CNKI, CBM, WanFang Data and VIP databases from inception to October 2016 to collect randomized controlled trials (RCTs) about different drugs for methamphetamine-induced psychotic disorders. Two reviewers independently screened literature, extracted data and assessed the risk bias of included studies, and then RevMan 5.3, R 3.3.2 and JAGS 4.2.0 softwares were used to perform network meta-analysis.ResultsA total of 16 RCTs involving 1 676 patients and 9 kinds of drugs were included. The results of network meta-analysis showed that: compared with the placebo group, olanzapine (OR=28.00, 95%CI 8.10 to 110.00), risperidone (OR=20.00, 95%CI 7.70 to 58.00), quetiapine (OR=30.00, 95%CI 6.60 to 160.00), ziprasidone (OR=28.00, 95%CI 3.70 to 230.00), chlorpromazine (OR=29.00, 95%CI 5.00 to 200.00), aripiprazole (OR=13.00, 95%CI 1.70 to 93.00), haloperidol (OR=19.00, 95%CI 2.10 to 190.00) could significantly improve the psychotic disorders of patients with methamphetamine, respectively, in which quetiapine was the best choice. There were no significant differences between any other pairwise comparisons of these different drugs.ConclusionFor the treatment of psychotic disorders caused by methamphetamine, quetiapine should be of a priority choice, follows by ziprasidone, chlorpromazine, olanzapine, risperidone, aripiprazole or haloperidol in a descending priority. Due to limited quality and quantity of the included studies, more high-quality studies are needed to verify above conclusion.

Citation： LI Fang, YIN Lei, YANG Haidong, CHEN Lizhang. Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(7): 835-842. doi: 10.7507/1672-2531.201702036 Copy

1.	崔麗. 80 例甲基苯丙胺所致精神障礙臨床研究. 中外醫療, 2015(8): 118-119.
2.	Patterns and trends of amphetamine-type stimulants and other drugs: challenges for Asia and the Pacific. UNODC, 2013. Available at: http://idpc.net/publications/2013/11/patterns-and-trends-of-amphetamine-type-stimulants-ats-and-other-drugs-challenges-for-asia-and-the-pacific-2013.
3.	Trends and patterns of amphetamine-type stimulants and new psychoactive substances. UNODC, 2015. Available at: https://www.unodc.org/documents/scientific/2013_Regional_ATS_Report_web.pdf.
4.	周永彬. 甲基苯丙胺所致精神障礙治療中奧氮平的應用效果觀察. 現代診斷與治療, 2015, 26(23): 5335-5336.
5.	Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol, 2012, 86(8): 1167-1231.
6.	王鋒銳, 葉百維, 王文軍. 濫用甲基苯丙胺與負性生活事件的相關性分析. 四川精神衛生, 2013, 26(2): 124-125.
7.	Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for healthcare decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health, 2011, 14(4): 423.
8.	曾憲濤, 張超. R 與 Meta 分析. 第一版. 北京: 軍事醫學科學出版社, 2015: 5.
9.	van Valkenhoef G, Lu GB, De Brock B, et al. Automating network meta-analysis. Res Synth Methods, 2012, 3(4): 285-299.
10.	Tunaru R. Hierarchical Bayesian models for multiple count data. Aust J Stat, 2002, 3(31): 221-229.
11.	易躍雄, 張蔚, 劉小媛, 等. 網狀 Meta 分析圖形結果解讀. 中國循證醫學雜志, 2015, 15(1): 103-109.
12.	潘建設. 奧氮平與利培酮治療冰毒所致精神障礙的臨床對照研究. 實用藥物與臨床, 2014, 17(3): 289-291.
13.	寸永海. 奧氮平治療冰毒所致精神障礙的臨床研究. 中國衛生產業, 2014, (28): 122-123.
14.	金蓮玉, 劉忠政. 應用奧氮平與利培酮治療冰毒所致精神障礙患者的對比分析. 中國民康醫學, 2016, 28(3): 57-58.
15.	祝昂明. 喹硫平治療甲基苯丙胺所致精神障礙的臨床觀察. 臨床醫藥文獻電子雜志, 2015, 2(3): 418-419.
16.	趙慶蓮, 侯峰, 張艷霞, 等. 喹硫平治療甲基苯丙胺所致精神障礙的臨床觀察. 中國藥物依賴性雜志, 2007, 16(6): 435-437.
17.	姚剛. 齊拉西酮治療甲基苯丙胺所致精神障礙臨床療效觀察. 實用醫院臨床雜志, 2011, 8(6): 126-128.
18.	周芳珍, 陸金進, 程琳. 氯丙嗪治療甲基苯丙胺所致精神障礙的療效觀察. 河北聯合大學學報(醫學版), 2013, 15(3): 317-318.
19.	潘建設, 劉林晶. 奧氮平與阿立哌唑治療冰毒所致精神障礙的臨床對照. 中國浙江金華: 浙江省醫學會精神病學分會學術年會暨浙江省醫師協會精神科醫師分會第六屆年會, 2013.
20.	趙慶蓮, 楊秋蘭, 侯峰, 等. 利培酮治療冰毒所致精神障礙 40 例療效觀察. 中國藥物濫用防治雜志, 2007, 13(6): 335-338.
21.	顏昌云, 余升晉, 魏筱龍. 利培酮治療冰毒所致精神障礙 50 例療效觀察. 中國藥物濫用防治雜志, 2010, 16(5): 281-282.
22.	Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction, 2014, 109(9): 1489-1500.
23.	Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 2013, 108(7): 1279-1286.
24.	Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychophacol, 2008, 33(5): 1162-1170.
25.	Anderson AL, Li SH, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 2015, 150: 170-174.
26.	Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend, 2008, 96(3): 222-232.
27.	Verachai V, Rukngan W, Chawanakrasaesin K, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology, 2014, 231(16): 3099-3108.
28.	Lappin JM, Sara GE, Farrell M. Methamphetamine-related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112(6): 927-928.
29.	Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry, 2012, 169(4): 389-396.
30.	Rawson RA. Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal, 2013, 21(4): S77-S81.
31.	Ohlssen D, Price KL, Xia HA, et al. Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. Pharm Stat, 2014, 13(1): 55-70.
32.	Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract, 2012, 24(6): 541-550.
33.	白錄東, 李萬順, 崔開艷, 等. 喹硫平基因組學研究進展. 精神醫學雜志, 2016, 29(3): 206-209.
34.	徐世超, 蘇閃芳, 陳智超. 齊拉西酮與利培酮治療首發精神分裂癥的療效和安全性. 當代醫學, 2013, 19(22): 137-138.

1. 崔麗. 80 例甲基苯丙胺所致精神障礙臨床研究. 中外醫療, 2015(8): 118-119.
2. Patterns and trends of amphetamine-type stimulants and other drugs: challenges for Asia and the Pacific. UNODC, 2013. Available at: http://idpc.net/publications/2013/11/patterns-and-trends-of-amphetamine-type-stimulants-ats-and-other-drugs-challenges-for-asia-and-the-pacific-2013.
3. Trends and patterns of amphetamine-type stimulants and new psychoactive substances. UNODC, 2015. Available at: https://www.unodc.org/documents/scientific/2013_Regional_ATS_Report_web.pdf.
4. 周永彬. 甲基苯丙胺所致精神障礙治療中奧氮平的應用效果觀察. 現代診斷與治療, 2015, 26(23): 5335-5336.
5. Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol, 2012, 86(8): 1167-1231.
6. 王鋒銳, 葉百維, 王文軍. 濫用甲基苯丙胺與負性生活事件的相關性分析. 四川精神衛生, 2013, 26(2): 124-125.
7. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for healthcare decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health, 2011, 14(4): 423.
8. 曾憲濤, 張超. R 與 Meta 分析. 第一版. 北京: 軍事醫學科學出版社, 2015: 5.
9. van Valkenhoef G, Lu GB, De Brock B, et al. Automating network meta-analysis. Res Synth Methods, 2012, 3(4): 285-299.
10. Tunaru R. Hierarchical Bayesian models for multiple count data. Aust J Stat, 2002, 3(31): 221-229.
11. 易躍雄, 張蔚, 劉小媛, 等. 網狀 Meta 分析圖形結果解讀. 中國循證醫學雜志, 2015, 15(1): 103-109.
12. 潘建設. 奧氮平與利培酮治療冰毒所致精神障礙的臨床對照研究. 實用藥物與臨床, 2014, 17(3): 289-291.
13. 寸永海. 奧氮平治療冰毒所致精神障礙的臨床研究. 中國衛生產業, 2014, (28): 122-123.
14. 金蓮玉, 劉忠政. 應用奧氮平與利培酮治療冰毒所致精神障礙患者的對比分析. 中國民康醫學, 2016, 28(3): 57-58.
15. 祝昂明. 喹硫平治療甲基苯丙胺所致精神障礙的臨床觀察. 臨床醫藥文獻電子雜志, 2015, 2(3): 418-419.
16. 趙慶蓮, 侯峰, 張艷霞, 等. 喹硫平治療甲基苯丙胺所致精神障礙的臨床觀察. 中國藥物依賴性雜志, 2007, 16(6): 435-437.
17. 姚剛. 齊拉西酮治療甲基苯丙胺所致精神障礙臨床療效觀察. 實用醫院臨床雜志, 2011, 8(6): 126-128.
18. 周芳珍, 陸金進, 程琳. 氯丙嗪治療甲基苯丙胺所致精神障礙的療效觀察. 河北聯合大學學報(醫學版), 2013, 15(3): 317-318.
19. 潘建設, 劉林晶. 奧氮平與阿立哌唑治療冰毒所致精神障礙的臨床對照. 中國浙江金華: 浙江省醫學會精神病學分會學術年會暨浙江省醫師協會精神科醫師分會第六屆年會, 2013.
20. 趙慶蓮, 楊秋蘭, 侯峰, 等. 利培酮治療冰毒所致精神障礙 40 例療效觀察. 中國藥物濫用防治雜志, 2007, 13(6): 335-338.
21. 顏昌云, 余升晉, 魏筱龍. 利培酮治療冰毒所致精神障礙 50 例療效觀察. 中國藥物濫用防治雜志, 2010, 16(5): 281-282.
22. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction, 2014, 109(9): 1489-1500.
23. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 2013, 108(7): 1279-1286.
24. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychophacol, 2008, 33(5): 1162-1170.
25. Anderson AL, Li SH, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 2015, 150: 170-174.
26. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend, 2008, 96(3): 222-232.
27. Verachai V, Rukngan W, Chawanakrasaesin K, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology, 2014, 231(16): 3099-3108.
28. Lappin JM, Sara GE, Farrell M. Methamphetamine-related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112(6): 927-928.
29. Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry, 2012, 169(4): 389-396.
30. Rawson RA. Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal, 2013, 21(4): S77-S81.
31. Ohlssen D, Price KL, Xia HA, et al. Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. Pharm Stat, 2014, 13(1): 55-70.
32. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract, 2012, 24(6): 541-550.
33. 白錄東, 李萬順, 崔開艷, 等. 喹硫平基因組學研究進展. 精神醫學雜志, 2016, 29(3): 206-209.
34. 徐世超, 蘇閃芳, 陳智超. 齊拉西酮與利培酮治療首發精神分裂癥的療效和安全性. 當代醫學, 2013, 19(22): 137-138.

Chinese Journal of Evidence-Based Medicine

Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content